Sanz-Santos José, Serra Mireia, Gallego Miguel, Montón Concepción, Cosio Borja, Sauleda Jaume, Fernández-Villar Alberto, García-Luján Ricardo, de Miguel Eduardo, Cordovilla Rosa, Varela Gonzalo, Cases Enrique, Andreo Felipe, Monsó Eduard
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Hospital Universitari del Parc Taulí, Sabadell, Spain Departament de Medicina, Universitat Autónoma de Barcelona, Bellaterra, Spain.
Eur J Cardiothorac Surg. 2015 Apr;47(4):642-7. doi: 10.1093/ejcts/ezu253. Epub 2014 Jul 8.
False-negative results of endobronchial ultrasound-guided transbronchial needle aspiration in non-small-cell lung cancer staging have shown significant variability in previous studies. The aim of this study was to identify procedure- and tumour-related determinants of endobronchial ultrasound-guided transbronchial needle aspiration false-negative results.
We conducted a prospective study that included non-small-cell lung cancer patients staged as N0/N1 by endobronchial ultrasound-guided transbronchial needle aspiration and undergoing therapeutic surgery. The frequency of false-negative results in the mediastinum was calculated. Procedure-related, first, and tumour-related, second, determinants of false-negative results in stations reachable and non-reachable by endobronchial ultrasound were determined by multivariate logistic regression.
False-negative endobronchial ultrasound-guided transbronchial needle aspiration results were identified in 23 of 165 enrolled patients (13.9%), mainly in stations reachable by endobronchial ultrasound (17 cases, 10.3%). False-negative results were related to the extensiveness of endobronchial ultrasound sampling: their prevalence was low (2.4%) when sampling of three mediastinal stations was satisfactory, but rose above 10% when this requirement was not fulfilled (P = 0.043). In the multivariate analysis, abnormal mediastinum on computer tomography/positron emission tomography [odds ratio (OR) 7.77, 95% confidence interval (CI) 2.19-27.51, P = 0.001] and extensiveness of satisfactory sampling of mediastinal stations (OR 0.37, 95% CI 0.16-0.89, P = 0.026) were statistically significant risk factors for false-negative results in stations reachable by endobronchial ultrasound. False-negative results in non-reachable nodes were associated with a left-sided location of the tumour (OR 10.11, 95% CI 1.17-87.52, P = 0.036).
The presence of false-negative ultrasound-guided transbronchial needle aspiration results were observed in nearly 15% of non-small-cell lung cancer patients but in only 3% when satisfactory samples were obtained from three mediastinal stations. False-negative results in stations reachable by endobronchial ultrasound were associated with the extensiveness of sampling, and in stations out of reach of endobronchial ultrasound with left-sided tumours. These results suggest that satisfactory sampling of at least three mediastinal stations by EBUS-TBNA may be a quality criterion to be recommended for EBUS-TBNA staging.
在既往研究中,支气管内超声引导下经支气管针吸活检术(EBUS-TBNA)在非小细胞肺癌分期中的假阴性结果显示出显著差异。本研究旨在确定EBUS-TBNA假阴性结果的操作相关和肿瘤相关决定因素。
我们进行了一项前瞻性研究,纳入了经EBUS-TBNA分期为N0/N1且接受治疗性手术的非小细胞肺癌患者。计算纵隔内假阴性结果的发生率。通过多因素逻辑回归确定EBUS可及和不可及部位假阴性结果的操作相关决定因素(首先)和肿瘤相关决定因素(其次)。
165例纳入患者中有23例(13.9%)出现EBUS-TBNA假阴性结果,主要发生在EBUS可及部位(17例,10.3%)。假阴性结果与EBUS采样范围有关:当三个纵隔部位采样满意时,其发生率较低(2.4%),但当未满足该要求时,发生率超过10%(P = 0.043)。在多因素分析中,计算机断层扫描/正电子发射断层扫描显示纵隔异常[比值比(OR)7.77,95%置信区间(CI)2.19 - 27.51,P = 0.001]以及纵隔部位满意采样范围(OR 0.37,95% CI 0.16 - 0.89,P = 0.026)是EBUS可及部位假阴性结果的统计学显著危险因素。不可及淋巴结的假阴性结果与肿瘤位于左侧有关(OR 10.11,95% CI 1.17 - 87.52,P = 0.036)。
在近15%的非小细胞肺癌患者中观察到EBUS-TBNA假阴性结果,但当从三个纵隔部位获得满意样本时,该比例仅为3%。EBUS可及部位的假阴性结果与采样范围有关,而在EBUS不可及部位,假阴性结果与左侧肿瘤有关。这些结果表明,EBUS-TBNA对至少三个纵隔部位进行满意采样可能是EBUS-TBNA分期推荐的质量标准。